alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
```

[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 9060 Introduced in House (IH)]

<DOC>

116th CONGRESS
  2d Session
                                H. R. 9060

 To amend section 1979 of the Revised Statutes of the United States to 
 clarify that States are persons for purposes of liability under that 
                    section, and for other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                           December 31, 2020

 Mr. Kennedy introduced the following bill; which was referred to the 
                       Committee on the Judiciary

_______________________________________________________________________

                                 A BILL

 
 To amend section 1979 of the Revised Statutes of the United States to 
 clarify that States are persons for purposes of liability under that 
                    section, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. FINDINGS.

    Congress finds the following:
            (1) The United States Supreme Court has held that the 
        Eleventh Amendment grants sovereign immunity to States in 
        Federal court absent a waiver by the State or congressional 
        action.
            (2) The United States Supreme Court has further held that a 
        lawsuit brought under section 1979 of the Revised Statutes of 
        the United States (42 U.S.C. 1983) against a government 
        official for actions taken in their official capacity is to be 
        treated as a lawsuit against the entity of which the officer is 
        an agent.
            (3) Due to sovereign immunity, lawsuits for actions brought 
        under such section may be filed against a State government 
        official in their personal capacity but not in their official 
        capacity.
            (4) This Act does not increase liability for government 
        officials in personal capacity cases in any way, but helps to 
        ensure equitable and monetary relief for victims of civil 
        rights violations.

SEC. 2. LIABILITY OF STATES FOR ACTIONS UNDER COLOR OF LAW.

    Section 1979 of the Revised Statutes of the United States (42 
U.S.C. 1983) is amended by adding at the end the following: ``For 
purposes of this section, the term `person' includes a State or 
Commonwealth, and a department, office, or officer acting in their 
official capacity, thereof.''
                                 <all>
```
No. 12-70.

#### Krikheli et ux. *v.*United States.

C. A. 2d Cir. Certiorari denied.
[Federal Register Volume 62, Number 50 (Friday, March 14, 1997)]
[Notices]
[Page 12162]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-6442]


-----------------------------------------------------------------------

DEPARTMENT OF ENERGY
[Docket No. ER94-24-017]


Enron Power Marketing, Inc.; Notice of Filing

March 10, 1997.
    Take notice that on January 21, 1997, Enron Power Marketing, Inc. 
tendered for filing a Notification of Change in Status.
    Any person desiring to be heard or to protest said filing should 
file a motion to intervene or protest with the Federal Energy 
Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in 
accordance with Rules 211 and 214 of the Commission's Rules of Practice 
and Procedure (18 CFR 385.211 and 18 CFR 385.214). All such motions or 
protests should be filed on or before March 20, 1997. Protests will be 
considered by the Commission in determining the appropriate action to 
be taken, but will not serve to make protestants parties to the 
proceeding. Any person wishing to become a party must file a motion to 
intervene. Copies of this filing are on file with the Commission and 
are available for public inspection.
Lois D. Cashell,
Secretary.
[FR Doc. 97-6442 Filed 3-13-97; 8:45 am]
BILLING CODE 6717-01-M
#### COM. v. MOYE, D.

1924 WDA 2016

Superior Court of Pennsylvania.

09/29/2017

CP-05-CR-0000486-2015

(Bedford)

Vacated/Remanded
No. 11-1311.

#### Dung Phan *v.*Holder, Attorney General.

C. A. 4th Cir. Certiorari denied.
EXHIBIT 21

                             Subsidiaries of the Registrant


Parent
------

Ramapo Financial Corporation

                                                State or Other
                                                Jurisdiction of   Percentage
Subsidiaries(1)                                 Incorporation     Ownership
---------------                                 -------------     ---------
The Ramapo Bank(2)                              New Jersey          100%
RFC High Ridge, Inc.                            New Jersey          100%
RFC Harmony Park, Inc.                          New Jersey          100%
RFC National, Inc.                              New Jersey          100%
RFC Center Plaza, Inc.                          New Jersey          100%
RFC High Debi Hills, Inc.                       New Jersey          100%
RFC Jefferson, Inc.                             New Jersey          100%
RFC Deer Trail Development, Inc.                New Jersey          100%
Ramapo Investment Corporation                   New Jersey          100%
Bancorps' International Trading Corporation(2)  New Jersey         33.3%

----------
(1)  Except for Bancorps' International Trading Corporation,  which is accounted
     for using the equity  method of  accounting,  the assets,  liabilities  and
     operations of the subsidiaries  are included in the consolidated  financial
     statements  contained in Item 8 hereof.  Unless  otherwise  indicated,  all
     subsidiaries are subsidiaries of the Bank.

(2)  Subsidiary of the Corporation.
# C_2023271EN.01002101.xml

| 31.7.2023 | EN | Official Journal of the European Union | C 271/21 |
| --- | --- | --- | --- |

31.7.2023

EN

Official Journal of the European Union

C 271/21

---

Order of the President of the Court of 17 March 2023 — European Commission v Portuguese Republic

(Case C-651/22) (1)

(2023/C 271/29)

Language of the case: Portuguese

The President of the Court has ordered that the case be removed from the register.

---

(1)  OJ C 463, 5.12.2022.

---
EXHIBIT 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Applied Imaging Corp. (the Company) on Form
10-Q for the period ended March 31, 2006 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Terence Griffin, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as
adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1) The Report fully complies with the
requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 15,
2006



|                       
|-----------------------
|/s/ TERENCE GRIFFIN    
|Terence Griffin        
|Chief Financial Officer

This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
No. 11-10737.

#### Melrose *v.*New York State Department of Health, Office of Professional Medical Conduct.

C. A. 2d Cir. Certiorari denied.
[Federal Register Volume 62, Number 53 (Wednesday, March 19, 1997)]
[Notices]
[Page 13169]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-6921]


-----------------------------------------------------------------------


DEPARTMENT OF JUSTICE

Importation of Controlled Substances; Notice of Application

    Pursuant to Section 1008 of the Controlled Substances Import and 
Export Act (21 U.S.C. 958(i)), the Attorney General shall, prior to 
issuing a registration under this Section to a bulk manufacturer of a 
controlled substance in Schedule I or II and prior to issuing a 
regulation under Section 1002(a) authorizing the importation of such a 
substance, provide manufacturers holding registrations for the bulk 
manufacture of the substance an opportunity for a hearing.
    Therefore, in accordance with Section 1311.42 of Title 21, Code of 
Federal Regulations (CFR), notice is hereby given that on May 6, 1996, 
Glaxo Wellcome Inc., Attn: Jeffrey A. Weiss, 1011 North Arendell 
Avenue, P.O. Box 1217, Zebulon, North Carolina 27597-2309, made 
application to the Drug Enforcement Administration to be registered as 
an importer of remifentanil (9739), which did not become a basic class 
of controlled substance in Schedule II until November of 1996. 
Therefore, this application was not processed until remifentanil was 
controlled and relevant statements of fact dated February 12, 1997, 
were received.
    The remifentanil is being imported for the production of Ultiva 
dosage forms and for research and new product development.
    Any manufacturer holding, or applying for, registration as a bulk 
manufacturer of this basic class of controlled substance may file 
written comments on or objections to the application described above 
and may, at the same time, file a written request for a hearing on such 
application in accordance with 21 CFR 1301.54 in such form as 
prescribed in 21 CFR 1316.47.
    Any such comments, objections, or requests for a hearing may be 
addressed to the Acting Deputy Assistant Administrator, Office of 
Diversion Control, Drug Enforcement Administration, United States 
Department of Justice, Washington, DC 20537, Attention: DEA Federal 
Register Representative (CCR), and must be filed no later than April 
18, 1997.
    This procedure is to be conducted simultaneously with and 
independent of the procedures described in 21 CFR 1311.42 (b), (c), 
(d), (e), and (f). As noted in a previous notice at 40 FR 43745-46 
(September 23, 1975), all applicants for registration to import basic 
classes of any controlled substances in Schedule I or II are and will 
continue to be required to demonstrate to the Acting Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration that the requirements for such registration pursuant to 
21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1311.42 (a), (b), (c), 
(d), (e), and (f) are satisfied.

    Dated: March 12, 1997.
Terrance W. Woodworth,
Acting Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration.
[FR Doc. 97-6921 Filed 3-18-97; 8:45 am]
BILLING CODE 4410-09-M
IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 17-41134

Conference Calendar

UNITED STATES OF AMERICA,

Plaintiff-Appellee

v.

ELIO MARROQUIN-LOPEZ,

Defendant-Appellant

Appeal from the United States District Court

for the Southern District of Texas

USDC No. 2:17-CR-393-1

Before DAVIS, JONES, and DUNCAN, Circuit Judges.

PER CURIAM:*

The Federal Public Defender appointed to represent Elio MarroquinLopez has moved for leave to withdraw and has filed a brief in accordance with 

Anders v. California, 386 U.S. 738 (1967), and United States v. Flores, 632 F.3d 

229 (5th Cir. 2011). Marroquin-Lopez has not filed a response. We have 

reviewed counsel’s brief and the relevant portions of the record reflected 

therein. We concur with counsel’s assessment that the appeal presents no 

 

* Pursuant to 5TH CIR. R. 47.5, the court has determined that this opinion should not 

be published and is not precedent except under the limited circumstances set forth in 5TH 

CIR. R. 47.5.4.

United States Court of Appeals

Fifth Circuit

FILED

July 9, 2018

Lyle W. Cayce

Clerk

 Case: 17-41134 Document: 00514545785 Page: 1 Date Filed: 07/09/2018
No. 17-41134

2

nonfrivolous issue for appellate review. Accordingly, counsel’s motion for leave 

to withdraw is GRANTED, counsel is excused from further responsibilities 

herein, and the APPEAL IS DISMISSED. See 5TH CIR. R. 42.2.

 Case: 17-41134 Document: 00514545785 Page: 2 Date Filed: 07/09/2018
<TABLE>
 





                                                                              EXHIBIT 11.1

                                     THE NEIMAN MARCUS GROUP, INC.


Computation of weighted average number of shares outstanding used in 
determining primary and fully diluted earnings per share:

<CAPTION>
(In thousands)               Twenty-Six Weeks Ended     Thirteen Weeks Ended 

                            February 1,  January 27,  February 1,  January 27,
                                   1997         1996         1997         1996

Primary

<S>                              <C>          <C>          <C>          <C>
1.  Weighted average number
    of common shares
    outstanding                  44,452       37,996       49,490       38,007


2.  Assumed exercise of
    certain stock options
    based on average
    market value                     175         167          163          231


3.  Weighted average number
    of shares used in primary
    per share computations       44,627       38,163       49,653       38,238





Fully diluted (A)

1.  Weighted average number
    of common shares
    outstanding                  44,452       37,996        49,490       38,007

           
2.  Assumed exercise of all
    dilutive options based
    on higher of average or
    closing market value            176          184          164          233

3.  Weighted average number
    of shares used in fully
    diluted per share
    computations                 44,628       38,180       49,654       38,240





   (A)  This calculation is submitted in accordance with Securities Exchange Act of l934 
        Release No. 9083 although not required by Footnote 2 to Paragraph l4 of APB Opinion
        No. l5 because it results in dilution of less than 3%.
</TABLE>
                                                   <PAGE>
[Federal Register Volume 62, Number 47 (Tuesday, March 11, 1997)]
[Notices]
[Page 11155]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-5892]


-----------------------------------------------------------------------


DEPARTMENT OF COMMERCE

Federal Highway Administration; Decision on Application for Duty-
Free Entry of Scientific Instrument

    This decision is made pursuant to Section 6(c) of the Educational, 
Scientific, and Cultural Materials Importation Act of 1966 (Pub. L. 89-
651, 80 Stat. 897; 15 CFR part 301). Related records can be viewed 
between 8:30 a.m. and 5 p.m. in Room 4211, U.S. Department of Commerce, 
14th and Constitution Avenue, NW, Washington, DC.
    Docket Number: 96-124. Applicant: Federal Highway Administration, 
McLean, VA 22101-2296. Instrument: ACFM Crack Microgauge, Model U9. 
Manufacturer: Technical Software Consultants, Ltd., United Kingdom. 
Intended Use: See notice at 62 FR 979, January 7, 1997.
    Comments: None received. Decision: Approved. No instrument of 
equivalent scientific value to the foreign instrument, for such 
purposes as it is intended to be used, is being manufactured in the 
United States. Reasons: The foreign instrument provides a 5 KHz drive 
coil and two directionally sensitive pickup coils employing alternating 
current field measurement to detect and size structural defects. A U.S. 
Department of Energy laboratory advised on February 11, 1997 that: (1) 
This capability is pertinent to the applicant's intended purpose and 
(2) it knows of no domestic instrument or apparatus of equivalent 
scientific value to the foreign instrument for the applicant's intended 
use.
    We know of no other instrument or apparatus of equivalent 
scientific value to the foreign instrument which is being manufactured 
in the United States.
Frank W. Creel,
Director, Statutory Import Programs Staff.
[FR Doc. 97-5892 Filed 3-10-97; 8:45 am]
BILLING CODE 3510-DS-P
I 

116TH CONGRESS 

1ST SESSION H. R. 966 

To repeal the Authorization for Use of Military Force. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 5, 2019 

Mr. GARAMENDI (for himself and Mr. JONES) introduced the following bill; 

which was referred to the Committee on Foreign Affairs 

A BILL 

To repeal the Authorization for Use of Military Force. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Walter B. Jones Re5 storing Power to Congress Act’’. 

6 SEC. 2. REPEAL OF AUTHORIZATION FOR USE OF MILITARY 

7 FORCE. 

8 Effective as of the date that is one year after the 

9 date of the enactment of this Act, the Authorization for 

10 Use of Military Force (Public Law 107–40; 50 U.S.C. 

11 1541 note) is repealed. 

Æ 


kjohnson on DSK79L0C42 with BILLS
IN THE SUPREME COURT OF PENNSYLVANIA

EASTERN DISTRICT

COMMONWEALTH OF PENNSYLVANIA,

Respondent

v.

MIGUEL A. PADILLA,

Petitioner :

:

:

:

:

:

:

:

:

:

: No. 9 EM 2021

ORDER

PER CURIAM

AND NOW , this 26th day of May , 2021, the Application for Leave to File a Reply

is GRANTED, and the Petition for Permission to Appeal is DENIED.
<TABLE>



                                             EXHIBIT 11.1
<CAPTION>
                                      THE NEIMAN MARCUS GROUP, INC.


Computation of weighted average number of shares outstanding used in determining primary and fully
diluted earnings per share:

                                                            Thirteen Weeks Ended    
(Shares in 000's)                                          November 2,    October 28,
                                                                  1996           1995


Primary

<S>                                                             <C>            <C>
1. Weighted average number of 
   common shares outstanding                                    39,413         37,984


2. Assumed exercise of certain
   stock options based on average
   market value                                                    188            104


3. Weighted average number of
   shares used in primary per
   share computations                                           39,601         38,088





Fully diluted (A)

1. Weighted average number of
   common shares outstanding                                    39,413         37,984


2. Assumed exercise of all dilutive
   options based on higher of average 
   or closing market value                                         190            135

3. Weighted average number of
   shares used in fully diluted 
   per share computations                                       39,603         38,119





(A)  This calculation is submitted in accordance with the Securities Exchange Act of 1934 Release No.
9083 although not required by Footnote 2 to Paragraph 14 of APB Opinion No. 15 because it results in
dilution of less than 3%.

</TABLE>
                                                           <PAGE>
# C_2023127EN.01003602.xml

| 11.4.2023 | EN | Official Journal of the European Union | C 127/36 |
| --- | --- | --- | --- |

11.4.2023

EN

Official Journal of the European Union

C 127/36

---

Judgment of the General Court of 15 February 2023 — Bambu Sales v EUIPO (BAMBU)

(Case T-82/22) (1)

(EU trade mark - Application for European Union word mark BAMBU - Absolute grounds for refusal - Descriptive character - Article 7(1)(b) and (c) of Regulation (EU) 2017/1001)

(2023/C 127/45)

Language of the case: English

Parties

Applicant: Bambu Sales, Inc. (Secaucus, New Jersey, United States) (represented by: T. Stein, lawyer)

Defendant: European Union Intellectual Property Office (represented by: M. Eberl and T. Frydendahl, acting as Agents)

Re:

By its action based on Article 263 TFEU, the applicant seeks annulment of the decision of the First Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 16 December 2021 (Case R 1702/2020-1).

Operative part of the judgment

The Court:

| 1. | Annuls the decision of the First Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 16 December 2021 (Case R 1702/2020-1) in so far as it concerns the following goods: vaporisers for the ingestion and inhalation of tobacco and other herbal matter; electronic smoking vaporisers, namely electronic cigarettes, and electronic smoking vaporisers for use as an alternative to traditional cigarettes; smoker’s vaporiser pipe cartridge sold empty; cigar cutters; electric cigarettes; electric cigars; electronic cigarettes; electronic cigarette refill cartridges sold empty; electronic cigars; hookah parts, namely hoses; liquefied gas cylinders for cigarette lighters; smoker’s articles, namely metal pocket-sized receptacles with lids for cigarette butts; smoking pipe cleaners; tobacco pipe cleaners; |
| --- | --- |

1.

Annuls the decision of the First Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 16 December 2021 (Case R 1702/2020-1) in so far as it concerns the following goods: vaporisers for the ingestion and inhalation of tobacco and other herbal matter; electronic smoking vaporisers, namely electronic cigarettes, and electronic smoking vaporisers for use as an alternative to traditional cigarettes; smoker’s vaporiser pipe cartridge sold empty; cigar cutters; electric cigarettes; electric cigars; electronic cigarettes; electronic cigarette refill cartridges sold empty; electronic cigars; hookah parts, namely hoses; liquefied gas cylinders for cigarette lighters; smoker’s articles, namely metal pocket-sized receptacles with lids for cigarette butts; smoking pipe cleaners; tobacco pipe cleaners;

| 2. | Dismisses the action as to the remainder; |
| --- | --- |

2.

Dismisses the action as to the remainder;

| 3. | Orders Bambu Sales, Inc. and EUIPO to bear their own costs. |
| --- | --- |

3.

Orders Bambu Sales, Inc. and EUIPO to bear their own costs.

---

(1)  OJ C 148, 4.4.2022.

---
No. 11-11104.

#### Fegan *v.*Gipson, Acting Warden (two judgments).

C. A. 9th Cir. Certiorari denied.